PSFE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
PSFE is not a good buy right now. The stock is in a clear downtrend (bearish moving-average stack, negative MACD), just broke below a key support zone near ~6.79, and there are no Intellectia proprietary buy signals to justify an aggressive, impatient entry. While RSI is near oversold and options positioning leans call-heavy (potential for a bounce), the recent analyst target cuts tied to a Q3 miss and FY25 guidance cut keep the risk skewed to further downside/range-bound trading rather than a clean reversal.
Trend is bearish: SMA_200 > SMA_20 > SMA_5 confirms sustained downside momentum. MACD histogram is negative (-0.0701) though contracting, which can precede stabilization but does not confirm a reversal. RSI_6 is ~29.4 (near oversold), suggesting short-term bounce potential, but oversold conditions can persist in strong downtrends. Price at 6.71 is slightly below S1 (6.792) and above S2 (6.45): this places PSFE in a vulnerable zone where a failed reclaim of ~6.79–7.35 (pivot 7.346) keeps the path of least resistance lower. Near-term pattern stats are weak/low-conviction (next day slightly negative bias; modest next-week upside estimate), not enough to offset the downtrend.
and S2 (6.
can attract short-covering or dip buyers. Options open interest is strongly call-skewed (put/call OI 0.17), which can support upside reflex moves if the stock reclaims the pivot (~7.35). Financials show slight revenue growth and improved net loss vs prior year (2025/Q3).
if buyers don’t step in quickly. No recent news catalyst to reverse sentiment. Hedge funds/insiders show neutral activity (no supportive accumulation signal). No recent politician/congress trading data to indicate influential buying support.
Latest quarter: 2025/Q3. Revenue rose to $433.8M (+1.57% YoY), indicating low single-digit top-line growth. Profitability remains weak: net income is still negative (-$87.7M), though it improved materially YoY (loss narrowed vs prior year), and EPS is -1.52 (also improved YoY). Gross margin was essentially flat/slightly higher (~41.95%). Overall: modest growth and improving loss profile, but still loss-making and the recent guidance cut (per analysts) implies near-term execution risk remains the dominant driver.
Recent analyst trend is negative: multiple major target cuts clustered around 2025-11-13/14 following Q3 results and a FY25 guidance reduction. UBS kept a Sell and cut PT to $7 (from $12). RBC kept Sector Perform and cut to $10 (from $17), citing concerning speed/magnitude of mix shift and longer timelines. Susquehanna stayed Neutral and cut to $9 (from $15), acknowledging early progress but still cautious. BTIG kept a Buy but cut PT to $11 (from $22), calling the implied Q4/EBITDA guide very bad. Wall Street pros: potential operational progress and possible FY26 EBITDA growth if management delivers. Cons: credibility hit from guidance cut, margin/mix headwinds, delayed initiatives, and expectation for range-bound trading until proof-points emerge.
